Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BSG 005

Next Previous
X
Search
Drug Profile

BSG 005

Alternative Names: BSG 005G; BSG-005

Latest Information Update: 28 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Greenlight Clinical; Norwegian university of science and technology; Nucleus Network; Select Pharma; SINTEF Materials and Chemistry
  • Developer Biosergen; Greenlight Clinical; Nucleus Network; Select Pharma
  • Class Antifungals; Macrolides; Polyenes
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mycoses
  • New Molecular Entity Yes
  • Available For Licensing Yes - Mycoses

Highest Development Phases

  • Phase I/II Mycoses

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for phase-I development in Mycoses(In volunteers, In adults) in Australia (IV, Infusion)
  • 01 Jul 2024 Phase-I/II clinical trials in Mycoses in India (IV) (NCT06678113)
  • 16 Jun 2021 Biosergen plans phase II trials for Mycoses in 2022 and 2023 (Biosergen pipeline, June 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top